Marc Dunoyer
Directeur Général chez ALEXION PHARMACEUTICALS, INC.
Profil
Marc Pierre Jean Dunoyer est directeur financier et directeur exécutif d'AstraZeneca Plc et siège au conseil d'administration de 5 autres sociétés. Il a précédemment occupé le poste de Global Head-Rare Diseases Unit chez GlaxoSmithKline Plc et de Président de GlaxoSmithKline KK (une filiale de GlaxoSmithKline Plc) et Président-Asie Pacifique chez Hoechst Marion Roussel SA. Il est titulaire d'un MBA des Hautes Etudes Commerciales et d'un diplôme d'études supérieures de l'Université de Paris IV Paris-Sorbonne.
Postes actifs de Marc Dunoyer
| Sociétés | Poste | Début |
|---|---|---|
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/08/2021 |
| ALEXION PHARMACEUTICALS, INC. | Directeur Général | - |
| CELLECTIS S.A. | Directeur/Membre du Conseil | 06/05/2024 |
Acerta Pharma BV
 Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | Directeur/Membre du Conseil | - |
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 07/06/2018 |
Astrazeneca Intermediate Holdings Ltd.
 Astrazeneca Intermediate Holdings Ltd. Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, AstraZeneca Intermediate Holdings Ltd. operates as a British intermediate holding company through its subsidiaries and researches, manufactures, and markets pharmaceuticals. The company is based in Cambridge, UK. | Directeur/Membre du Conseil | - |
AstraZeneca UK Ltd.
 AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 29/11/2013 |
AstraZeneca KK
 AstraZeneca KK Pharmaceuticals: MajorHealth Technology AstraZeneca KK develops, manufactures and sells prescription drugs. It also conducts medical research. The company was founded on April 11, 1975 and is headquartered in Osaka, Japan. | Président | - |
| Alexion Pharmaceuticals, Inc. /New/ | Directeur Général | 01/08/2021 |
Anciens postes connus de Marc Dunoyer
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Marc Dunoyer
| Hautes Etudes Commerciales | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| GSK PLC | Health Technology |
| JCR PHARMACEUTICALS CO., LTD. | Health Technology |
| ASTRAZENECA PLC | Health Technology |
| CELLECTIS S.A. | Health Technology |
| Entreprise privées | 11 |
|---|---|
| Hoechst Marion Roussel SA | Health Technology |
GlaxoSmithKline KK
 GlaxoSmithKline KK Household/Personal CareConsumer Non-Durables GlaxoSmithKline KK researches, develops, imports, manufactures and sells toiletry products. The company was founded on August 18, 1928 and is headquartered in Tokyo, Japan | Consumer Non-Durables |
| Université de Paris IV Paris-Sorbonne | Consumer Services |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | Health Technology |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Astrazeneca Intermediate Holdings Ltd.
Astrazeneca Intermediate Holdings Ltd. Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, AstraZeneca Intermediate Holdings Ltd. operates as a British intermediate holding company through its subsidiaries and researches, manufactures, and markets pharmaceuticals. The company is based in Cambridge, UK. | Health Technology |
AstraZeneca UK Ltd.
AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom. | Commercial Services |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
AstraZeneca KK
AstraZeneca KK Pharmaceuticals: MajorHealth Technology AstraZeneca KK develops, manufactures and sells prescription drugs. It also conducts medical research. The company was founded on April 11, 1975 and is headquartered in Osaka, Japan. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
| Alexion Pharmaceuticals, Inc. /New/ |
